Long-term outcomes of adults with congenital heart disease and 1.5 ventricle repair

IF 6.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation Pub Date : 2025-03-18 DOI:10.1016/j.healun.2024.12.020

Alexander C. Egbe MD, MPH, MS, FACC , William R. Miranda MD , Heidi M. Connolly MD , Joseph A. Dearani MD

{"title":"Long-term outcomes of adults with congenital heart disease and 1.5 ventricle repair","authors":"Alexander C. Egbe MD, MPH, MS, FACC , William R. Miranda MD , Heidi M. Connolly MD , Joseph A. Dearani MD","doi":"10.1016/j.healun.2024.12.020","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The 1.5 ventricle repair is a palliative procedure for patients with congenital heart disease with advanced right heart failure. There are limited data about patient selection and outcomes of this procedure. The purpose of this study was to describe the clinical and hemodynamic characteristics, and outcomes of adults with congenital heart disease (CHD) and 1.5 ventricle repair.</div></div><div><h3>Method</h3><div>We studied adults with CHD that underwent 1.5 ventricle repair and received care at Mayo Clinic between January 1, 2003, and December 31, 2023. The patients were divided into two cohorts. Cohort #1 comprised of patients that had 1.5 ventricle repair prior to adulthood (age <18 years), while Cohort #2 comprised of patients that underwent 1.5 ventricle repair in adulthood (age ≥18 years).</div></div><div><h3>Results</h3><div>There were 61 patients with 1.5 ventricle repair (Cohort #1 <em>n</em>=39, 64%; Cohort #2 <em>n</em>=22, 36%). In Cohort #1, the median age at the time of 1.5 ventricle repair was 7 years (interquartile range [IQR]: 1–12), while the median age at presentation to the CHD clinic was 20 years (IQR: 18–27). Of the 39 patients in Cohort #1, 4 (10%) required reintervention. The 10-year risk of death/transplant was 14%. In Cohort #2, the median age at the time of 1.5 ventricle repair was 33 years (IQR: 23–44), and the operative mortality was 4%. There was an improvement in cardiac output, functional status, and reduction in the proportion of patients with stage D heart failure at 1 year after 1.5 ventricle repair.</div></div><div><h3>Conclusions</h3><div>The 1.5 ventricle repair is a viable treatment option in patients with advanced heart failure and may delay the need for heart transplant.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 4","pages":"Pages 511-520"},"PeriodicalIF":6.4000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Heart and Lung Transplantation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053249824020345","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The 1.5 ventricle repair is a palliative procedure for patients with congenital heart disease with advanced right heart failure. There are limited data about patient selection and outcomes of this procedure. The purpose of this study was to describe the clinical and hemodynamic characteristics, and outcomes of adults with congenital heart disease (CHD) and 1.5 ventricle repair.

Method

We studied adults with CHD that underwent 1.5 ventricle repair and received care at Mayo Clinic between January 1, 2003, and December 31, 2023. The patients were divided into two cohorts. Cohort #1 comprised of patients that had 1.5 ventricle repair prior to adulthood (age <18 years), while Cohort #2 comprised of patients that underwent 1.5 ventricle repair in adulthood (age ≥18 years).

Results

There were 61 patients with 1.5 ventricle repair (Cohort #1 n=39, 64%; Cohort #2 n=22, 36%). In Cohort #1, the median age at the time of 1.5 ventricle repair was 7 years (interquartile range [IQR]: 1–12), while the median age at presentation to the CHD clinic was 20 years (IQR: 18–27). Of the 39 patients in Cohort #1, 4 (10%) required reintervention. The 10-year risk of death/transplant was 14%. In Cohort #2, the median age at the time of 1.5 ventricle repair was 33 years (IQR: 23–44), and the operative mortality was 4%. There was an improvement in cardiac output, functional status, and reduction in the proportion of patients with stage D heart failure at 1 year after 1.5 ventricle repair.

Conclusions

The 1.5 ventricle repair is a viable treatment option in patients with advanced heart failure and may delay the need for heart transplant.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Heart and Lung Transplantation 医学-呼吸系统

CiteScore

10.10

自引率

6.70%

发文量

1667

审稿时长

69 days

期刊介绍： The Journal of Heart and Lung Transplantation, the official publication of the International Society for Heart and Lung Transplantation, brings readers essential scholarly and timely information in the field of cardio-pulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. Importantly, the journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.